RxDoctor Payments Data

Bill Byrd, MD

Family Medicine · Longwood, FLNPI 1174511323

Payments from drug & device makers

$4,152in general payments, 2019–2025

Across 134 payments — averaging $30.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$896
  • GSK$304
  • Johnson & Johnson$293
  • Lilly USA, LLC$290
  • Amarin Pharma, Inc.$287
  • plus $821 from 10 others

What the payments were for

  • Food & beverage$4,12899%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,152 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$11,288
Medicare patients
56
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide97$130,563
EliquisApixaban90$116,670
TrulicityDulaglutide75$95,418
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$75,358
JardianceEmpagliflozin60$62,267
FarxigaDapagliflozin Propanediol38$45,312
RybelsusSemaglutide19$39,972
OzempicSemaglutide26$38,082
Keppra XrLevetiracetam15$18,137
MyrbetriqMirabegron17$11,774
XareltoRivaroxaban18$11,666
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,751
LumiganBimatoprost12$3,398
Gabapentin167$3,232
Levothyroxine Sodium240$2,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$290$225,981172 claims
PfizerEliquis$106$116,67090 claims
Novo NordiskRybelsus, Ozempic$213$78,05345 claims
GSKTrelegy Ellipta$304$75,35868 claims
Boehringer IngelheimJardiance$896$62,26760 claims
AstraZenecaFarxiga$1,262$45,31238 claims
Johnson & JohnsonXarelto$293$11,66618 claims
AbbVieLumigan$18$3,39812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Longwood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →